Leadership

Michael Brainard, Ph.D.

Director

[email protected]

 

Howard Fields, MD, PhD

Howard Fields, MD, PhD

Motivation, punishment and reward circuits
Neurology
Emeritus

Howard Fields received his MD and PhD in Neuroscience at Stanford in 1965-66. After Internal Medicine training at Bellevue Hospital in New York, he spent three years as a research neurologist at Walter Reed Army Institute of Research. Following clinical training in neurology at the Boston City Hospital Service of Harvard Medical School in 1972, he joined the faculty of the University of California San Francisco. Fields major interests are in nervous system mechanisms of pain and substance abuse with a focus on how endogenous opioids contribute to these mechanisms. He was a founder of the UCSF pain management center and has made major contributions to understanding and treating neuropathic pain. His group was the first to demonstrate the clinical effectiveness of opioids for neuropathic pain and of topical lidocaine for post-herpetic neuralgia. In laboratory studies he discovered and elucidated a pain modulating neural circuit that is required for opioids to produce analgesia. He also discovered that placebo analgesia is blocked by an opioid antagonist. Recently, his laboratory has discovered nerve cells in the striatum that selectively encode the magnitude of a reward. They have also shown how the neurotransmitter dopamine contributes to motivation and reward based choice. Current work is focused on the neurobiology of opioid reward.

Publications: 

International Association for the Study of Pain publications over the 50-year span.

Davis KD, Basbaum AI, Bushnell MC, Yarnitsky D, Fields HL

Pain modulates dopamine neurons via a spinal-parabrachial-mesencephalic circuit.

Yang H, de Jong JW, Cerniauskas I, Peck JR, Lim BK, Gong H, Fields HL, Lammel S

A Midbrain Circuit that Mediates Headache Aversiveness in Rats.

Waung MW, Margolis EB, Charbit AR, Fields HL

Endogenous opioid activity in the anterior cingulate cortex is required for relief of pain.

Navratilova E, Xie JY, Meske D, Qu C, Morimura K, Okun A, Arakawa N, Ossipov M, Fields HL, Porreca F

Understanding opioid reward.

Fields HL, Margolis EB

Direct bidirectional µ-opioid control of midbrain dopamine neurons.

Margolis EB, Hjelmstad GO, Fujita W, Fields HL

Parceling human accumbens into putative core and shell dissociates encoding of values for reward and pain.

Baliki MN, Mansour A, Baria AT, Huang L, Berger SE, Fields HL, Apkarian AV

Capturing the aversive state of cephalic pain preclinically.

De Felice M, Eyde N, Dodick D, Dussor GO, Ossipov MH, Fields HL, Porreca F

Pain relief produces negative reinforcement through activation of mesolimbic reward-valuation circuitry.

Navratilova E, Xie JY, Okun A, Qu C, Eyde N, Ci S, Ossipov MH, King T, Fields HL, Porreca F

Identification of rat ventral tegmental area GABAergic neurons.

Margolis EB, Toy B, Himmels P, Morales M, Fields HL

Dopamine, corticostriatal connectivity, and intertemporal choice.

Kayser AS, Allen DC, Navarro-Cebrian A, Mitchell JM, Fields HL

Corticostriatal functional connectivity predicts transition to chronic back pain.

Baliki MN, Petre B, Torbey S, Herrmann KM, Huang L, Schnitzer TJ, Fields HL, Apkarian AV

Varenicline decreases alcohol consumption in heavy-drinking smokers.

Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL

Engagement of descending inhibition from the rostral ventromedial medulla protects against chronic neuropathic pain.

De Felice M, Sanoja R, Wang R, Vera-Portocarrero L, Oyarzo J, King T, Ossipov MH, Vanderah TW, Lai J, Dussor GO, Fields HL, Price TJ, Porreca F

Nucleus accumbens medium spiny neurons target non-dopaminergic neurons in the ventral tegmental area.

Xia Y, Driscoll JR, Wilbrecht L, Margolis EB, Fields HL, Hjelmstad GO

Reliability in the identification of midbrain dopamine neurons.

Margolis EB, Coker AR, Driscoll JR, Lemaître AI, Fields HL

Unmasking the tonic-aversive state in neuropathic pain.

King T, Vera-Portocarrero L, Gutierrez T, Vanderah TW, Dussor G, Lai J, Fields HL, Porreca F

Immediate reward bias in humans: fronto-parietal networks and a role for the catechol-O-methyltransferase 158(Val/Val) genotype.

Boettiger CA, Mitchell JM, Tavares VC, Robertson M, Joslyn G, D'Esposito M, Fields HL

The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers.

Mitchell JM, Fields HL, White RL, Meadoff TM, Joslyn G, Rowbotham MC

Endogenous opioid blockade and impulsive responding in alcoholics and healthy controls.

Mitchell JM, Tavares VC, Fields HL, D'Esposito M, Boettiger CA

Endogenous opioids encode relative taste preference.

Taha SA, Norsted E, Lee LS, Lang PD, Lee BS, Woolley JD, Fields HL

Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex.

Margolis EB, Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL

Impulsive responding in alcoholics.

Mitchell JM, Fields HL, D'Esposito M, Boettiger CA

Pain and the placebo: what we have learned.

Hoffman GA, Harrington A, Fields HL

Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons.

Margolis EB, Hjelmstad GO, Bonci A, Fields HL

Capsaicin evoked pain and allodynia in post-herpetic neuralgia.

Petersen KL, Fields HL, Brennum J, Sandroni P, Rowbotham MC

Comments on Thurston and Randich.

Fields HL, Heinricher MM